EP1240199A2 - Procede de criblage d'agents de regulation de l'appetit - Google Patents

Procede de criblage d'agents de regulation de l'appetit

Info

Publication number
EP1240199A2
EP1240199A2 EP00993643A EP00993643A EP1240199A2 EP 1240199 A2 EP1240199 A2 EP 1240199A2 EP 00993643 A EP00993643 A EP 00993643A EP 00993643 A EP00993643 A EP 00993643A EP 1240199 A2 EP1240199 A2 EP 1240199A2
Authority
EP
European Patent Office
Prior art keywords
gpr12
receptor
appetite control
control agent
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00993643A
Other languages
German (de)
English (en)
Inventor
John Charles Brennand
Andrew David Charles
Kevin Anthony Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1240199A2 publication Critical patent/EP1240199A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Definitions

  • This invention relates to the regulation of metabolism and in particular to human genes involved in appetite control or obesity.
  • the invention also relates to the identification of ligands that interact with such genes and the provision of therapeutic agents.
  • Obesity is now a major health problem. Currently 22.5% of the US population is considered to be clinically obese, 18.5% in the UK and with many other developed countries following this trend. It has been described as the most extensive non-communicable disease of the 21 st century. Currently available treatments are reviewed by M. Lean in Exp. Clin. Endocrinol. Diabetes, 1998, 106, Suppl. 2, 22-26. These include diet and, in extreme cases, surgery.
  • Leptin is a hormone secreted by adipose tissue which, along with it's receptor, are integral parts of the complex physiological system which has evolved to regulate and control energy balance and storage at an optimal level (Freidman JM and Halaas JL (1998) Nature 395, 763-769).
  • Leptin also appears to play an important role in relaying nutritional status to several other physiological systems.
  • the relevance of leptin to the pathogenesis of obesity in general is the subject of much study and underlines the complex nature of human obesity.
  • a human obesity gene map is now available and the number of genes and other markers that have been associated or linked with human obesity phenotypes now approaches 200.
  • the chosen targets include enzymes, hormones, neurotransmitters as well as the so-called G-protein-coupled- receptors (GPCR's).
  • GPCR's represent one of the largest families of genes so far identified. Over 800 family members have been cloned to date from a wide variety of species.
  • Our investigations have now revealed that the mR A coding for the GPCR GPR12 is differentially expressed in murine appetite/obesity models. It follows that non-peptidic compounds acting on GPR12, will have utility in controlling food intake and metabolic processes.
  • GPR12 is a known gene.
  • the human version was first disclosed by Song et al (Genomics, 1995, 28, 347-349).
  • the human cDNA was isolated via the screening of a human cosmid library using its rat homologue as a probe.
  • the human GPR12 cDNA is derived from a single exon and encodes a 334 amino acid protein It is presently an orphan receptor.
  • Also known are the mouse and rat genes (Saeki Y, FEBS Lett., 1993, 336:317-322 and Eidne K.A., FEBS Lett., 1991, 292:243-248).
  • a method for the provision of an appetite control agent which method comprises using one or more agonists and/or antagonists of the G protein coupled receptor GPR12 as test compounds in one or more appetite control test procedures, and selecting an active compound for use as an appetite control agent.
  • Convenient appetite control test procedures include the use of animal models to test the role of the test compound in appetite control and obesity. These will typically involve the administration of compounds by intra peritoneal injection, subcutaneous injection, intravenous injection, oral gavage or direct injection via canullae into the CNS of experimental animals. The effects on food intake, body temperature, metabolic rate, behavioural activities and body weight changes may all be measured using standard procedures.
  • Suitable antagonists or agonists may be firstly identified by screening for agonists and/or antagonists of the GPR12 receptor.
  • an appetite control agent which method comprises (i) screening the GPR12 receptor for agonists and/or antagonists of the receptor and (ii) using one or more agonists and/or antagonists so identified as test compounds in one or more appetite control test procedures, and selecting an active compound for use as an appetite control agent.
  • the GPR12 receptor is from any mammalian species, including human, monkey, rat, mouse and dog. For screening purposes this is conveniently the human GPR12 receptor.
  • the mammalian GPR12 receptors may be conveniently isolated from commercially available RNA, brain cDNA libraries, genomic DNA, or genomic DNA libraries using conventional molecular biology techniques such as library screening and/or Polymerase Chain Reaction (PCR).
  • a natural ligand to these cells causes activation of the transfected receptor that will cause changes in the levels of intracellular signalling molecules such as cyclic AMP, intracellular calcium ions or arachidonic acid metabolite release. These may all be measured using standard published procedures and commercially available reagents.
  • these cD ⁇ A's may be transfected into derivatives of these cells lines that have previously been transfected with a "reporter” gene such as bacterial LacZ, Luciferase, aquorin or green fluorescent protein that will "report” these intracellular changes.
  • the natural ligand for GPR12 is not yet known.
  • the cells transfected with GPR12 are used to find natural ligands that will activate GPR12.
  • the ligands used for this activity are sourced commercially or synthesised chemically ( Lembo et al., 1999, Nature Cell Biol., 1, 267-271 ) or may be purified from mammalian sources such as animal brain extracts ( Saurai et al., 1998, cell, 92, 573-585) ). Once identified, purified radiolabelled or fluorescently labelled material (eg. Amersham PLC & Advanced Bioconcept Ltd) may be used as a ligand to detect ligand binding to these transfected receptors using standard published ligand binding assay technologies.
  • transfected cell lines may be used to identify low molecular weight compounds that activate these receptors and cause changes in the intracellular signalling molecules, these are defined as "agonists”.
  • test compound may be a polypeptide of equal to or greater than, 2 amino acids such as up to 6 amino acids, up to 10 or 12 amino acids, up to 20 amino acids or greater than 20 amino acids such as up to 50 amino acids.
  • preferred compounds are chemical compounds of low molecular weight and potential therapeutic agents. They are for example of less than about 1000 Daltons, such as less than 800, 600 or 400 Daltons in weight. If desired the test compound may be a member of a chemical library.
  • This may comprise any convenient number of individual members, for example tens to hundreds to thousands to millions etc., of suitable compounds, for example peptides, peptoids and other oligomeric compounds (cyclic or linear), and template-based smaller molecules, for example benzodiazepines, hydantoins, biaryls, carbocyclic and polycyclic compounds (eg. naphthalenes, phenothiazines, acridines, steroids etc.), carbohydrate and amino acids derivatives, dihydropyridines, benzhydryls and heterocycles (eg. triazines, indoles, thiazolidines etc.).
  • Preferred chemical libraries comprise chemical compounds of low molecular weight and potential therapeutic agents.
  • an antagonist of a GPR12 receptor as an appetite control agent. It will be appreciated that the present invention includes the use of orthologues and homologues of the human GPR12 receptor.
  • orthologue we mean the functionally equivalent receptor in other species.
  • homologue we mean a substantially similar and/or related receptor in the same or a different species.
  • the receptors may have for example at least 30%, such as at least 40%, at least 50% , at least 60%, and in particular at least 70%, such as at least 80%, for example 85%), or 90% or 95%> peptide sequence identity. It is appreciated that homologous receptors may have substantially higher peptide sequence identity over small regions representing functional domains. We include receptors having greater diversity in their DNA coding sequences than outlined for the above amino acid sequences but which give rise to receptors having peptide sequence identity falling within the above sequence ranges. Convenient versions of the GPR12 receptor include the published sequence (Song et al.ibid) and the sequence identities Nos.l to 6 set out in the attached sequence listing.
  • Fragments and partial sequences of the GPR12 receptor may be useful substrates in the assay and analytical methods of the invention. It will be appreciated that the only limitation on these is practical, they must comprise the necessary functional elements for use in the relevant assay and/or analytical procedures.
  • a method of appetite control which method comprises administering to an individual a pharmaceutically effective amount of an appetite control agent identified using one or more of the methods of this invention.
  • the appetite control agent of this invention may be administered in standard manner for the condition that it is desired to treat, for example by oral, topical, parenteral, buccal, nasal, or rectal administration or by inhalation.
  • the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
  • GPR12 receptor also provides the ability to regulate its expression in vivo by for example the use of antisense DNA or RNA.
  • an appetite control agent comprising an antisense DNA or an antisense RNA which is complementary to all or a part of a polynucleotide sequences shown in sequence Nos.l, 3 and 5.
  • complementary we mean that the two molecules can hybridise to form a double stranded molecule through nucleotide base pair interactions to the exclusion of other molecular interactions .
  • the antisense DNA or RNA for co-operation with polynucleotide sequence corresponding to all or a part of a GPR12 gene can be produced using conventional means, by standard molecular biology and/or by chemical synthesis.
  • the antisense DNA or RNA can be complementary to the full length GPR12 receptor gene of the invention or to a fragment thereof.
  • Antisense molecules which comprise oligomers in the range from about 12 to about 30 nucleotides which are complementary to the regions of the gene which are proximal to, or include, the protein coding region, or a portion thereof, are preferred embodiments of the invention
  • the antisense DNA or antisense RNA may be chemically modified so as to prevent degradation in vivo or to facilitate passage through a cell membrane and/or a substance capable of inactivating mRNA, for example ribozyme, may be linked thereto and the invention extends to such constructs.
  • Oligonucleotides which comprise sequences complementary to and hybridizable to the
  • GPR12 receptor are contemplated for therapeutic use.
  • U.S. Patent No. 5,639,595 Identification of Novel Drugs and Reagents, issued Jun. 17, 1997, wherein methods of identifying oligonucleotide sequences that display in vivo activity are thoroughly described, is herein incorporated by reference.
  • Nucleotide sequences that are complementary to the GPR12 receptor encoding nucleic acid sequence can be synthesised for antisense therapy. These antisense molecules may be DNA, stable derivatives of DNA such as phosphorothioates or methylphosphonates, RNA, stable derivatives of RNA such as 2'-O-alkylRNA, or other oligonucleotide mimetics.
  • GPR12 gene antisense molecules may be introduced into cells by micro injection, liposome encapsulation or by expression from vectors harbouring the antisense sequence.
  • Transgenic animal technology may also be used, providing new experimental models, useful for evaluating the effects of test compounds on the control of obesity and eating disorders.
  • GPR12 may be deleted, inactivated or modified using standard procedures as outlined briefly below and as described for example in "Gene Targeting; A Practical Approach", IRL Press, 1993.
  • the target gene or a portion of it, for example homologous sequences flanking the coding region is preferably cloned into a vector with a selection marker (such as Neo) inserted into the gene to disrupt its function.
  • the vector is linearised then transformed (usually by electroporation) into embryonic stem cells (ES) cells (eg derived from a 129/Ola strain of mouse) and thereafter homologous recombination events take place in a proportion of the stem cells.
  • ES embryonic stem cells
  • the stem cells containing the gene disruption are expanded and injected into a blastocyst (such as for example from a C57BL/6J mouse) and implanted into a foster mother for development.
  • Chimaeric offspring may be identified by coat colour markers. Chimeras are bred to ascertain the contribution of the ES cells to the germ line by mating to mice with genetic markers which allow a distinction to be made between ES derived and host blastocyst derived gametes. Half of the ES cell derived gametes will carry the gene modification.
  • Offspring are screened (for example by Southern blotting) to identify those with a gene disruption (about 50% of the progeny). These selected offspring will be heterozygous and may therefore be bred with another heterozygote to produce homozygous offspring (about 25% of the progeny).
  • Transgenic animals with a target gene deletion may be crossed with transgenic animals produced by known techniques such as microinjection of DNA into pronuclei, spheroplast fusion or lipid mediated transfection of ES cells to yield transgenic animals with an endogenous gene knockout and a foreign gene replacement.
  • ES cells containing a targeted gene disruption may be further modified by transforming with the target gene sequence containing a specific alteration. Following homologous recombination the altered gene is introduced into the genome.
  • embryonic stem cells may subsequently be used to create transgenics as described above.
  • the transgenic animals will display a phenotype, which reflects the role of GPR12 in the control of appetite and obesity and will thus provide useful experimental models in which to evaluate the effects of test compounds.
  • transgenic animals in which GPR12 is deleted, inactivated or modified, and used in evaluating the effects of test compounds in appetite control and obesity.
  • the GPR12 receptor may also be used as the basis for diagnosis, for example to determine expression levels in a human subject, by for example direct DNA sequence comparison or DNA/RNA hybridisation assays. Diagnostic assays may involve the use of nucleic acid amplification technology such as PCR and in particular the Amplification Refractory Mutation System (ARMS) as claimed in our European Patent No. 0 332 435. Such assays may be used to determine allelic variants of the gene, for example insertions, deletions and/or mutations such as one or more point mutations.
  • Amplification Refractory Mutation System as claimed in our European Patent No. 0 332 435.
  • Such assays may be used to determine allelic variants of the gene, for example insertions, deletions and/or mutations such as one or more point mutations.
  • Such variants may be heterozygous or homozygous.
  • Other approaches have been used to identify mutations in genes encoding similar molecules in obese patients (Yeo et al., 1998, Nature Genetics, 20, 111-112).
  • the GPR 12 receptor can be genetically engineered in such a way that its interactions with other intracellular and membrane associated proteins are maintained but its effector function and biological activity are removed.
  • the genetically modified protein is known as a dominant negative mutant. Overexpression of the dominant negative mutant in an appropriate cell type down regulates the effect of the endogenous protein, thus revealing the biological role of the genes in appetite control.
  • the GPR12 receptor may also be genetically engineered in such a way that its effector function and biological activity are enhanced.
  • the resultant overactive protein is known as dominant positive mutant.
  • Overexpression of a dominant positive mutant in an appropriate cell type amplifies the biological response of the endogenous, native protein, spotlighting its role in appetite control.
  • This also has utility in a screen for detecting antagonists of the constitutively active receptor in the absence of a ligand. Therefore, in a further aspect of the invention we provide dominant negative and dominant positive mutants of a GPR12 receptor and their use in evaluating the biological role of the GPR12 receptor in the control of appetite.
  • PCR Cloning of GPR12 Oligonucleotide primers of 30 nucleotides in length corresponding to sequences immediately 5' of the initiating ATG codon and immediately 3' of the termination codon for the coding sequences of human and rat GPR12 (sequences below) are synthesised.
  • Commercial sources of rat and human brain RNA are used as templates in standard RT-PCR reactions with these primers.
  • RT-PCR primers are designed to incorporate nucleotides coding for tag sequences e.g. myc, His 6 to facilitate purification of the proteins at a later stage.
  • RT-PCR kits are used in accordance with the suppliers' instructions and as documented in the Sambrook reference cited above.
  • Products of the PCR vector are cloned using standard technology (ibid.) into the plasmid vector pBluescript (Stratagene Ltd.).
  • Plasmid DNA is isolated (ibid.) and subjected to DNA sequence analysis (ibid.) to identify a clone containing the GPR12 sequence identical to those published (below).
  • the inserts corresponding to GPR12 cDNA are released from this DNA using standard digestion procedures and with appropriate restriction endonuclease enzymes.
  • the inserts are then cloned into suitably prepared plasmid DNA using standard technology (ibid.). These plasmids are the expression vectors used in the studies described below.
  • mammalian expression vectors may be used to express the recombinant GPR12 molecule as well as variants contemplated herein.
  • mammalian expression vectors which are suitable for recombinant expression, include but are not limited to, the pcDNA3 series (InNitrogen), pMClneo (Stratagene), pXTl (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593) pBPV-1 (8-2) (ATCC 37110), pdBPN- MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and 1ZD35 (ATCC 37565), pLXI ⁇ and pSIR (CLO ⁇ TECH), p
  • Plasmid D ⁇ A's containing the GPR12 cD ⁇ A inserts are then purified (ibid.) and introduced into appropriate host cells, (ii) a vector is described for use with the Mouse Erythroleukaemia Cells (MEL) expression system using the human beta globin gene locus control region (Davies et al., J of Pharmacol & Toxicol. Methods, 33, 153-158.). This vector system and derivatives thereof will be used. Plasmid D ⁇ A's containing the GPR12 cD ⁇ A inserts are then purified (ibid.) and introduced into appropriate host cells.
  • MEL Mouse Erythroleukaemia Cells
  • the GPR12 can be used to raise diagnostic antibodies as to detect the biomolecule in cultured cells and in vivo. Therefore, in accordance with yet a further aspect of the present invention, there are provided antibodies against the GPR12 receptor polypeptide which may used as part of various diagnostic assays for detecting physiological eating disorders.
  • An example for the production of effective polyclonal antibodies against peptides derived from the known amino acid sequences of GPR12 receptors utilises a well-established algorithm method developed by Jameson and Wolf.
  • the antigenic Index A novel Algorithm for Predicting Antigenic Determinants, CABIOS, 4:181 (1988).
  • Peptide molecules of typically between 10-20 amino acid residues are synthesised chemically and conjugated to keyhole limpet hemocyanin and used for antibody generation by GE ⁇ OSYS BIOTECHNOLOGIES,
  • Specific antibodies may be raised by immunising animals, with rabbits being preferred, with an appropriate concentration of the GPR12 peptides either with or without an immune adjuvant.
  • Monospecific antibodies to the polypeptide of the present invention are purified from mammalian antisera containing antibodies reactive against the GPR12 using the technique of Kohler and Milstein, Nature, 256:495 (1975).
  • Mono-specific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for the novel signal transduction molecule.
  • Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with sequence Nos. 2,4 & 6.
  • Monoclonal antibodies are produced in vivo by injection of pristine primed Balb/c mice, approximately 0.5 ml per mouse, with about 2 x 10 6 to about 6 x 10 6 hybridoma cells about 4 days after priming.
  • Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.
  • In vitro production of the anti-polypeptide mAb is carried out by growing the hybridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb.
  • the mAb are purified by techniques known in the art.
  • mammalian expression vector plasmid DNA is introduced (ibid.) into cultured mammalian cells.
  • Eukaryotic recombinant host cells are especially preferred. Examples include but are not limited to yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to Drosophila and silkworm derived cell lines.
  • L cells L-M(TK-) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616),BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171) and HEK293 (ATCC CRL 1573).
  • DNA is introduced into variants of these cell lines that have previously been transfected and selected to express other proteins such as ⁇ -galactosidase, or mutated G-proteins such as Gal 6 (Milligan et al, 1996, TiPS, 17, 235-237).
  • Clones of mammalian cells expressing GPR12 cDNA are identified by selecting mammalian cell clones that have been selected on the basis of their resistance to antibiotics due to the presence of appropriate resistance genes on the parental plasmids (See Maniatis, et al), by RT-CPR of the introduced sequences and by detection of protein using specific antibodies. .
  • the expression vectors may be introduced into host cells expressing GPR12 via any one of a number of techniques including but not limited to transformation, transfection, lipofection, protoplast fusion, and electroporation.
  • Commercially available kits applicable for use with the present invention for heterologous expression including well-characterised vectors, transfection reagents and conditions, and cell culture materials are well-established and readily available. [CLONTECH, Palo Alto, CA; InNitrogen, Carlsbad, CA; PHARM ⁇ GE ⁇ , San Diego, CA; STRATAGENE, LaJolla, CA.]
  • Identification of the natural ligand for the GPR12 receptor entails successive purification and assay steps using rat, porcine, or other animal brain as starting material. Homogenised brain tissue is fractionated by conventional biochemical methods and fractions are screened for activity in the reporter cell assays described below. Detailed protocols for these methods are available Sakurai, et al. 1998, Cell, 92:573-585. Successive purification procedures yield a purified ligand for GPR12 that is characterised by sequencing methodologies (ibid.). Cell Binding Assay
  • Mammalian cells isolated from the selection procedures described above are cultured by standard techniques and exposed to 125 [I] ligand once it is identified. Following extensive washing of cells to remove unbound material the extent of ligand binding is quantitated in a Gammamaster counter (Packard) using the methods described in detail by Davies et al. (op cit). Cell clones showing the greatest binding of this ligand are progressed to the next phase of this process.
  • the mammalian cell clones identified by the method described above are cultured, harvested and used as the source of membrane preparation.
  • Membranes are prepared from these cell clones by standard biochemical techniques that are described in detail by Davies et al. (op cit).
  • Cells expressing GPR12 are identified as described above. These cells have also been engineered to express the LacZ gene coupled to the mammalian cyclic AMP response element (Egerton et al, J.Mol.Endocrinol, 1995, 14(2), 179-189). When cAMP levels increase in the cell the transcription of the LacZ gene is proportionately increased and may be measured by standard beta-galactosidase assays (Maniatis et al., ibid.).
  • GPR12 are also engineered to express the G-protein Get 16 (Milligan et al., 1996, TiPS, 17, 235-237. Upon activation the cells respond by increasing intracellular Calcium concentrations. This increase is measured after pre-exposure of the cells to afluorescent compound such as, but not limited to, Fura2 (Molecular Probes Ltd) and reading on any commercially available fluorescence analysing equipment (Lembo et al., 1999, Nature Cell Biol, 1, 267-271 )
  • afluorescent compound such as, but not limited to, Fura2 (Molecular Probes Ltd) and reading on any commercially available fluorescence analysing equipment (Lembo et al., 1999, Nature Cell Biol, 1, 267-271 )
  • Cells expressing GPR12 are also assayed for the increased release of radiolabelled arachidonic acid (AA) metabolites following pre-incubation of the cells to 3[H] arachidonic acid and stimulation by ligand, once identified (Davies et al., ibid.).
  • AA arachidonic acid
  • these compounds are applied to the mammalian cells in the presence and absence of ligand and those compounds that influence the output of the assays described above are identified.
  • the reporter cells containing GPR12 are exposed to chemical compounds in the absence of any ligand, and assayed, as described, for changes in intracellular cAMP, and Ca++ as well as for increased arachidonic acid metabolite release.
  • Antagonists The GPR12 cDNA's are mutated by standard Molecular biology techniques (Sambrook, ibid.) and transfected into the mammalian reporter cells, as described. Cell lines harbouring mutated receptors that give increased reporter gene activity are then used to screen chemical compounds for their ability to suppress this reporter gene activity through antagonising these constitutively active receptors.
  • Animals identified from the assays described above are considered for testing in animal models.
  • Appropriately formulated compounds are administered by, but not limited to, oral gavage, intraperitoneal, intravenous, intramuscular or intracerebrovascular injection or infusion.
  • Animals will include, but are not limited to, standard laboratory rodents, dogs and primates, obese Zucker rats, obese (ob/ob) mice diabetic (db/db) mice and the transgenic "knockout" animals described above. These animals may be fed standard laboratory diets, or may be offered altered diets, including but not limited to, diets designed to induce hyperphagia and weight gain (eg. high fat, high carbohydrate) (Stock, 1998, Clinical Obesity, Oxford Press, 50-72).
  • GPRC_Mouse Probable G Protein-Coupled Receptor GPR12 (GPCRO 1).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de mise à disposition d'un agent de régulation d'appétit consistant à utiliser un ou plusieurs agonistes ou antagonistes du récepteur GPR12 comme composés tests dans une ou plusieurs procédures tests de régulation d'appétit, et à choisir un composé actif destiné à être utilisé comme régulateur d'appétit.
EP00993643A 1999-12-10 2000-12-05 Procede de criblage d'agents de regulation de l'appetit Withdrawn EP1240199A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16994499P 1999-12-10 1999-12-10
US169944P 1999-12-10
PCT/GB2000/004631 WO2001048483A2 (fr) 1999-12-10 2000-12-05 Compose

Publications (1)

Publication Number Publication Date
EP1240199A2 true EP1240199A2 (fr) 2002-09-18

Family

ID=22617859

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00993643A Withdrawn EP1240199A2 (fr) 1999-12-10 2000-12-05 Procede de criblage d'agents de regulation de l'appetit

Country Status (4)

Country Link
EP (1) EP1240199A2 (fr)
JP (1) JP2003518628A (fr)
AU (1) AU5787901A (fr)
WO (1) WO2001048483A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003276106A1 (en) * 2002-10-24 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
EP1662862A1 (fr) * 2003-09-19 2006-06-07 Paradigm Therapeutics Limited Recepteur
ATE483981T1 (de) * 2004-04-20 2010-10-15 Galapagos Nv Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion
US8221990B2 (en) 2007-04-06 2012-07-17 Teijin Pharma Limited Screening GPR12 receptor for substances having Nesfatin-1-like action, or which regulate Nesfatin-1 action
JP2010527375A (ja) * 2007-05-15 2010-08-12 ヘリコン セラピューティクス，インコーポレイテッド Ｇｐｒ１２の阻害による認知障害の治療方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130880A (en) * 1997-04-14 2004-03-28 Arena Pharm Inc Method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
JP2002507422A (ja) * 1998-03-23 2002-03-12 スミスクライン ビーチャム コーポレーション ヒトＧタンパク質共役型受容体ＧＰＲ６ｓｂ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0148483A2 *

Also Published As

Publication number Publication date
JP2003518628A (ja) 2003-06-10
WO2001048483A2 (fr) 2001-07-05
AU5787901A (en) 2001-07-09
WO2001048483A3 (fr) 2002-01-10

Similar Documents

Publication Publication Date Title
AU747846B2 (en) Human potassium channel genes
JP2003501088A (ja) 脂質輸送タンパク質
US6528303B1 (en) Neuropeptide Y-Y5 receptor
JP2003501026A (ja) 脂質代謝転写因子
EP1240199A2 (fr) Procede de criblage d'agents de regulation de l'appetit
CA2390723A1 (fr) Cellules presentant une carence du recepteur de la melanocortine 3, animaux transgeniques et methodes de selection de composes regulant le poids corporel
US20040053812A1 (en) Methods
US20020040132A1 (en) Methods
US9618521B2 (en) Sperm-specific cation channel, Catsper2, and uses therefor
US20020082412A1 (en) Methods
US20050250720A1 (en) Novel compound
CA2462670A1 (fr) Canal cations catsper2 specifique du sperme et utilisations correspondantes
US6399761B1 (en) Nucleic acid encoding human potassium channel K+ nov1 protein
US5776762A (en) Obesity associated genes
CA2379462A1 (fr) Nouveau recepteur couple a la proteine g humaine
WO1999038975A2 (fr) Sequences polynucleotidiques et polypeptidiques associees a un phenomene de sensibilite aux depresseurs du systeme nerveux central
AU772193B2 (en) Neuropeptide Y-Y5 receptor
US20040067887A1 (en) Human VNO receptor (R1)
CA2390740A1 (fr) Cellules deficientes en recepteurs 4 de melanocortine, animaux transgeniques non humains et procedes de selection de composes qui regulent le poids corporel
US20030143541A1 (en) Human pheromone receptors
US20030196212A1 (en) Novel pheromone receptor
WO2003087140A1 (fr) Fxrb de non-primate comme recepteur hormonal nucleaire sensible au lanosterol et utilisations associees
WO2002018421A2 (fr) Molecules

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020710

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030923

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050823